Cited by 240Cystic Fibrosis Research AdvancesBacterial biofilms and quorum sensingChronic Obstructive Pulmonary Disease (COPD) Research

Changes in cystic fibrosis airway microbiota at pulmonary exacerbation

Open access
Carmody, Lisa A., Zhao, Jiangchao, Schloss, Patrick D., Petrosino, Joseph F., Murray, Susan, Young, Vincent B., Li, Jun Z., LiPuma, John J.·2013·Annals of the American Thoracic Society

Abstract

RATIONALE: In persons with cystic fibrosis (CF), repeated exacerbations of pulmonary symptoms are associated with a progressive decline in lung function. Changes in the airway microbiota around the time of exacerbations are not well understood. OBJECTIVES: To characterize changes in airway bacterial communities around the time of exacerbations and to identify predictors for these changes. METHODS: DNA prepared from 68 paired baseline and exacerbation sputum samples collected from 28 patients with CF were subjected to barcoded 16S rRNA gene pyrosequencing. Bacterial density was calculated by quantitative PCR. MEASUREMENTS AND MAIN RESULTS: Overall, significant differences in bacterial community diversity and bacterial density between baseline and exacerbation samples were not observed. However, considerable changes in community structures were observed in a subset of patients. In these patients, the dominant taxa and initial level of community diversity were significant predictors of the magnitude of community structure changes at exacerbation. Pseudomonas-dominant communities became more diverse at exacerbation compared with communities with other or no dominant species. The relative abundance of Gemella increased in 24 (83%) of 29 samples at exacerbation and was found to be the most discriminative genus between baseline and exacerbation samples. CONCLUSIONS: The magnitude of changes in the CF lung microbiota around the time of exacerbation was found to be largely dependent on community diversity and composition at baseline. Certain genera appear to play important roles in driving change in airway bacterial community composition at exacerbation. Gemella might play a direct role in and/or be a biomarker for pulmonary exacerbation.

Integrity signals

Registry

Crossref · 10.1513/annalsats.201211-107oc

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Culture-independent studies comparing bacterial communities at baseline and during exacerbations in the airways of patients with COPD, cystic fibrosis, or bronchiectasis consistently report no increase in bacterial burden and no decrease in community diversity during exacerbations.

    “With remarkable consistency, all studies report no increase in bacterial burden and no decrease in community diversity during exacerbations.”

    From The microbiome and critical illness (2016) · cites this paper as [136]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Carmody, L. A., Zhao, J., Schloss, P. D., Petrosino, J. F., Murray, S., Young, V. B., Li, J. Z., & LiPuma, J. J.
Affiliations
  • University of Michigan (US)
  • Microbiology and Immunology
  • Baylor College of Medicine (US)
  • Departments of Pediatrics and Communicable Disease and
Corresponding author
LiPuma, John J.
Venue
Annals of the American Thoracic Society
Published
2013-06-01
Volume
10
Issue
3
Pages
179-187
ISSN
  • 2325-6621 (ISSN-L)
  • 2329-6933
OpenAlex
W2129800212
Cited by
239
References
34
Citations by year
2026: 4 · 2025: 10 · 2024: 12 · 2023: 19 · 2022: 19 · 2021: 19 · 2020: 23 · 2019: 22 · 2018: 18 · 2017: 28 · 2016: 17 · 2015: 30 · 2014: 15 · 2013: 3
FWCI
17.61
Type
journal article
Language
en
Open access
Locations
  • Annals of the American Thoracic Society (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Cystic Fibrosis Foundation
  • Georgia Clinical and Translational Science Alliance
  • National Institutes of Health (5rc1hl100809-02)
  • National Heart, Lung, and Blood Institute (U01HL098961, RC1-HL100809, 1RC1HL100809-01)
  • National Human Genome Research Institute (R01HG005975, R01HG004906)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034933)
  • National Center for Research Resources (UL1RR024986)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Keywords
cystic fibrosis, pulmonary exacerbations, airway microbiome, bacterial community diversity, community composition, Pseudomonas, Gemella, biomarkers, lung function decline
MeSH terms
Adolescent, Adult, Child, Cystic Fibrosis, Female, Humans, Lung, Male, Middle Aged, Sputum, Disease Progression, Young Adult, Microbiota

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review